Here are your research findings and updates for November, 2021. Stay up to date on monthly research developments with us! Sanguine is currently recruiting for 51 research studies. Check out the latest Sanguine studies here.
Gene Therapies for Rare Diseases: The National Institute of Health (NIH), Food and Drug Administration (FDA), 1o pharmaceutical companies, and 5 non-profit organizations have partnered together to accelerate gene therapies for rare diseases. 30 million Americans are suffering from 7,000 rare diseases and most of these diseases are caused by a defect in a single gene.
All of Us: In 2018, the NIH launched the All of Us Research Program, an effort to enroll a million individuals across the United States with the goal of advancing precision medicine. Historically, research efforts mostly pertained to those of European and caucasian descent. The goal of All of Us, is for diverse individuals to enroll and contribute their medical information and data so that researchers can develop more personalized and successful treatments.
COVID-19 Brain Fog: A new study found that individuals who suffered from COVID-19 are now dealing with cognitive issues like memory loss and brain fog. One theory is that the brain fog is a result of chronic inflammation caused by the COVID-19 virus.
Sickle Cell Disease Research News Updates
SCD and Kidney Transplants: Patients with sickle cell disease may experience many complications including kidney failure. Studies have showed that kidney transplant reduced mortality risk for sickle cell patients with kidney complications compared to dialysis. However, sickle cell patients are often less likely to receive a transplant, which demonstrates health inequity for these patients.
Machine Learning for Kidneys: Sickle cell patients are at high risk for developing chronic kidney disease. With a grant from the NIH, researchers, Dr. Ataga and Dr. Saraf, have developed machine learning tools that can identify sickle cell patients who are at high-risk of developing kidney disease to slow progression and begin treatment.
Lupus Research News Updates
4 Lupus Subgroups: A new research study identifies 4 different lupus subgroups. The study analyzed autoantibodies in over 900 lupus patients and found specific autoantibody groupings in each subgroup that present with specific physical symptoms. These findings suggest that there may be multiple pathways involved in the progression of lupus that may influence treatments.
Belimumab and Rituximab: A recent clinical trial study showed that lupus research participants treated with belimumab after rituximab had significantly lower lupus antibody levels and had reduced risk of a severe lupus flare. These findings suggest that this combination may be used as a treatment strategy.